ADGM (Adagio Medical Holdings, Inc Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ADGM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Timothy P. Moran | Director | A | — | — |
| 2026-08-12 | SANDRA A. GARDINER | Director | A | — | — |
| 2026-08-12 | Keyvan Mirsaeedi-Farahani | Director | A | — | — |
| 2026-08-12 | ORLY MISHAN | Director | A | — | — |
| 2026-08-12 | Sean Salmon | Director | A | — | — |
| 2026-08-12 | James L Cox | Director | A | — | — |
| 2026-03-09 | Todd Usen | Chief Executive Officer | A | — | — |
| 2026-03-09 | Deborah Kaster | Chief Financial Officer | A | — | — |
| 2025-12-18 | Deborah Kaster | Chief Financial Officer | Buy | — | — |
| 2025-12-15 | Todd Usen | Chief Executive Officer | Buy | — | — |
| 2025-12-11 | Sean Salmon | Director | A | — | — |
| 2025-10-22 | JOSEPH EDELMAN | 10%+ Owner | Buy | — | — |
| 2025-03-21 | ORLY MISHAN | Director | A | — | — |
| 2025-03-21 | SANDRA A. GARDINER | Director | A | — | — |
| 2025-03-21 | James L Cox | Director | A | — | — |
| 2025-03-21 | Timothy P. Moran | Director | A | — | — |
| 2025-03-21 | Keyvan Mirsaeedi-Farahani | Director | A | — | — |
| 2025-02-14 | PERCEPTIVE ADVISORS LLC | Director | A | — | — |
| 2025-02-13 | Todd Usen | Chief Executive Officer | A | — | — |
| 2024-10-01 | ARYA Sciences Holdings IV | 10%+ Owner | J | — | — |
| 2024-08-02 | James L Cox | Director | J | — | — |
| 2024-08-02 | Hakon Bergheim | Chief Operating Officer | J | — | — |
| 2024-08-02 | OLAV BERGHEIM | CEO | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 9,876,586 | — |
| — | Chief Executive Officer | 207,315 | — |
| — | Director | 36,698 | — |
| — | CEO | 22,081 | — |
| — | Chief Financial Officer | 15,000 | — |
| — | Chief Operating Officer | 7,539 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADGM quote page; the site-wide leaderboard is on the insider transactions hub.